China’s Alphamab raises $100M in Series A financing from US, Asian investors
The Suzhou-based firm plans to use the money to advance its therapies, currently in clinical development in China and Australia.
The Suzhou-based firm plans to use the money to advance its therapies, currently in clinical development in China and Australia.